Grifols (GRFS)
(Delayed Data from NSDQ)
$8.95 USD
-0.13 (-1.43%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $8.96 +0.01 (0.11%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth C Momentum C VGM
Company Summary
Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.
Company Summary
General Information
Grifols, SA
152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL?S
BARCELONA, U3 08174
Phone: 34-93-571-2200
Fax: 34-93-800-8000
Email: investors@grifols.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | NA |
EPS Information
Current Quarter EPS Consensus Estimate | 0.24 |
Current Year EPS Consensus Estimate | 0.79 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | NA |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 9.08 |
52 Week High | 12.15 |
52 Week Low | 5.30 |
Beta | 0.50 |
20 Day Moving Average | 1,223,729.25 |
Target Price Consensus | 11.25 |
4 Week | 1.13 |
12 Week | 42.06 |
YTD | -22.58 |
4 Week | -1.21 |
12 Week | 36.59 |
YTD | -34.43 |
Shares Outstanding (millions) | NA |
Market Capitalization (millions) | NA |
Short Ratio | NA |
Last Split Date | 1/4/2016 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 11.40 |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -77.78% |
vs. Previous Quarter | NA |
vs. Previous Year | 8.11% |
vs. Previous Quarter | NA% |
Price/Book | 0.71 |
Price/Cash Flow | 11.34 |
Price / Sales | NA |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 1.73 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 0.66 |
6/30/24 | 1.68 |
3/31/24 | NA |
12/31/23 | 2.79 |
6/30/24 | 0.80 |
3/31/24 | NA |
12/31/23 | 1.29 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 2.16 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 0.90 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 3.40 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 12.55 |
6/30/24 | Pending Next EPS Report |
3/31/24 | NA |
12/31/23 | 1.21 |
6/30/24 | 1.06 |
3/31/24 | NA |
12/31/23 | 1.26 |
6/30/24 | 51.34 |
3/31/24 | NA |
12/31/23 | 55.72 |